Vicept Therapeutics Announces Positive Phase 2 Data of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea) - Drugs.com MedNews
Links shared publicly online about this topic.
- 592total visits
Vicept Therapeutics Announces Positive Phase 2 Data of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea) - Drugs.com MedNews
-Highly statistically significant improvement in primary endpoint of facial redness associated with rosacea- Malvern, PA January 10, 2011 Vicept Therapeutics, I
View full resource at drugs.com
Most Recently Shared on January 9, 2011 at 11:16 pm By:
Vicept Therapeutics Announces Positive Phase 2 Data of V-101 for the Treatment of Type I Rosacea (Erythema... http://bit.ly/fl3CLf #drug
Advertisement
